Short fiber carrier medicine, preparation method thereof and application of short fiber carrier medicine in preparation of medicine for treating ulcerative enteritis

Abstract

The invention discloses a short fiber carrier drug, a preparation method thereof and application of the short fiber carrier drug in preparation of drugs for treating ulcerative enteritis. The carrier medicine comprises rutin as a traditional Chinese medicine monomer and a glucan carrier. The short fiber carrier medicine can be used as a medicine for treating ulcerative enteritis, and high-efficiency medicine carrying capacity is achieved by means of hydrophilic / hydrophobic interaction, pi-pi accumulation and other non-covalent interaction. The carrier drug has a micro / nano fiber structure, so that the anti-inflammatory ability of the drug is greatly improved, and effective treatment of ulcerative enteritis is realized. Therefore, the novel carrier drug provided by the invention has a slow release effect, can synergistically regulate the immune environment, can reduce the medication frequency and reduce the drug resistance, and realizes more effective treatment of ulcerative enteritis.

Description

Technical Field

[0001] The invention relates to the field of short fiber carrier drugs, and in particular to a short fiber carrier drug and a preparation method thereof and application of the short fiber carrier drug in preparing drugs for treating ulcerative enteritis. Background Art

[0002] Ulcerative colitis (UC) is a major subtype of inflammatory bowel disease (IBD), a chronic, relapsing gastrointestinal disease of unknown etiology, with a rapidly increasing incidence worldwide. UC is characterized by diffuse mucosal inflammation of the distal colon and rectum, accompanied by rectal bleeding, diarrhea, abdominal pain, and weight loss, and often presents with complications requiring hospitalization and surgical treatment, which negatively affects the daily life activities of UC patients. Rutin, a natural flavonoid compound, is considered to be an effective candidate for the treatment of UC. Its multiple biological activities contribute to UC, including anti-inflammatory, antioxidant, intestinal barrier repair, and microbiota regulation. However, the application of rutin is severely limited by its low water solubility, low bioavailability, and poor membrane permeability. To address this problem, various morphological drug delivery systems such as micelles, microspheres, and nanoparticles have been widely adopted to meet the needs of biomedical applications. For example, the rutin drug delivery system established by physical interaction is limited by factors such as system instability, low drug loading efficiency, and burst release of rutin; for chemically modified rutin carrier drugs, the preparation process of their conjugates is complicated and accompanied by the loss of active sites. Therefore, the goal of the present invention is to explore and prepare a new carrier drug, provide a theoretical basis for the design, development and safe application of drug delivery systems, and provide a new therapeutic drug for the treatment of UC. Summary of the invention

[0003] The purpose of the present invention is to design and prepare a short fiber carrier medicine and a preparation method thereof and use the short fiber carrier medicine in preparing medicine for treating ulcerative enteritis.

[0004] A novel method for preparing a "short fiber" carrier drug, which has a simple synthesis, and the carrier drug prepared by the method can be used as a therapeutic drug for ulcerative enteritis. The present invention solves the technical problem by adopting the following technical solutions.

[0005] A method for preparing a short fiber carrier drug comprises the following steps:

[0006] First, dissolve rutin in ethanol to prepare solution A;

[0007] Dissolve dextran in a mixture of pure water and acetic acid to prepare solution B;

[0008] Solution A is added to solution B and stirred to dissolve, and bubbles are removed by ultrasonication. The solution is refrigerated and allowed to stand for a period of time. A fibrous product is obtained through post-treatment as a short fiber carrier drug.

[0009] Furthermore, the present invention provides a method for preparing a short fiber carrier drug, which comprises: first dissolving the Chinese medicine monomer rutin in anhydrous ethanol and dissolving it thoroughly to prepare solution A. Secondly, dissolving a certain molecular weight of dextran in a mixture of pure water and acetic acid to prepare solution B. Add solution B to solution A and stir to dissolve, remove bubbles by ultrasound, and refrigerate for a period of time. Filter the above-mentioned mixture and wash it with pure water, freeze it, and freeze-dry it to obtain a fibrous product. This product is the "short fiber" carrier drug.

[0010] The concentration of rutin in the solution A is 1-5 mg / ml.

[0011] The molecular weight of the dextran is 6w to 50w.

[0012] The pure water and acetic acid mixed solution is prepared by mixing pure water and acetic acid in a volume ratio of 50 to 110:1.

[0013] The refrigerated storage and standing conditions are: 2-6° C. refrigerated storage and standing for 2-5 days.

[0014] The post-processing includes:

[0015] The mixed solution after refrigeration and standing is filtered and the solid product is washed with pure water and collected, and freeze-dried to obtain a fibrous product. The freeze-drying conditions are: freeze-drying at -85°C to -75°C for 8 to 16 hours.

[0016] The short fiber carrier drug prepared by the preparation method is used in preparing drugs for treating ulcerative enteritis.

[0017] The beneficial effect of the preparation method of a novel "short fiber" carrier drug of the embodiment of the present invention is that the "short fiber" carrier drug prepared by the present invention can exert the powerful therapeutic effect of Rutin while minimizing the systemic effect. In short, Rutin and DEX form co-assembled fibers (RT / DEX) through non-covalent interactions such as hydrophilic / hydrophobic interactions and π-π stacking; the Rutin encapsulation efficiency is 60±5.5%, and the three-day release rate is 51±1.0%. It can maintain the stability of the stomach and release Rutin in the colon, and its designed pH sensitivity is contributed by the polysaccharide-based structure. It was further found that RT / DEX can easily accumulate in the intestinal inflammation site in the colitis mouse model, and its therapeutic effect is better than that of clinical drugs (sulfasalazine). After RT / DEX co-assembled fiber treatment, typical inflammatory factors can be significantly inhibited and the release of anti-inflammatory factors can be promoted. In addition, RT / DEX can also significantly improve the intestinal barrier function and intestinal flora. Therefore, the carrier drug has broad prospects for clinical application.

[0018] Compared with the prior art, the present invention has the following advantages:

[0019] In the present invention, the carrier drug is a Chinese medicine monomer rutin and a dextran carrier. The "short fiber" carrier drug involved in the present invention can be used as a drug for the treatment of ulcerative enteritis, and utilizes non-covalent interactions such as hydrophilic / hydrophobic interactions and π-π stacking to achieve a high-efficiency drug loading capacity. The micro / nano fiber structure of the carrier drug greatly improves the anti-inflammatory ability of the drug and achieves an effective treatment of ulcerative enteritis. Therefore, the new carrier drug provided by the present invention has a sustained release effect and can synergistically regulate the immune environment, can reduce the number of medications, reduce drug resistance, and achieve a more effective treatment of ulcerative enteritis. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0021] Figure 1 The apparent images of the "short fiber" carrier drugs provided in Examples 1 and 10 of the present invention.

[0022] Figure 2 Microscopic images of the carrier drug "short fibers" provided in Examples 1, 2, 3, 4, and 5 of the present invention.

[0023] Figure 3 This is a statistical graph of drug loading rates provided for Example 1, Example 2, Example 3, Example 4, and Example 5 of the present invention.

[0024] Figure 4 This is a statistical graph of hemolysis rates provided for Example 1, Example 2, Example 3, Example 4, and Example 5 of the present invention.

[0025] Figure 5 This is a statistical graph of cell activity provided by Example 1, Example 2, Example 3, Example 4, and Example 5 of the present invention.

[0026] Figure 6 The figure is a graph showing the changes in body weight after administration of a commercial drug (sulfasalazine) and Example 1 of the present invention in an acute UC mouse model induced by dextran sodium sulfate (DSS).

[0027] Figure 7 The figure is a statistical chart of intestinal changes after administration of commercial drugs (sulfasalazine) and Example 1 of the present invention in an acute UC mouse model induced by dextran sodium sulfate (DSS).

[0028] Figure 8The figure is a statistical graph of spleen weight ratio after administration of commercial drug (sulfasalazine) and Example 1 of the present invention in the acute UC mouse model induced by dextran sodium sulfate (DSS).

[0029] Fig. 9 The disease activity score diagram (based on the scores of weight change, intestinal changes, degree of bloody stool, stool consistency, etc.) after administration of commercial drugs (sulfasalazine) and Example 1 of the present invention in the acute UC mouse model induced by dextran sodium sulfate (DSS).

[0030] Fig.10 It is the KEEG analysis diagram of Example 1 and the control group. DETAILED DESCRIPTION

[0031] In order to make the purpose, technical scheme and advantages of the embodiment of the present invention clearer, the technical scheme in the embodiment of the present invention will be described clearly and completely below. The reagents or instruments used without indicating the manufacturer are all conventional products that can be purchased commercially. The preparation method of the novel "short fiber" carrier drug in the embodiment of the present invention is specifically described below.

[0032] The present invention provides a method for preparing a novel "short fiber" carrier drug, which comprises: dissolving the Chinese medicine monomer rutin in 10 ml of anhydrous ethanol and dissolving it completely to prepare solution A. In a preferred embodiment of the present invention, the rutin concentration is preferably 3 mg / ml.

[0033] Dextran with a certain molecular weight is dissolved in a mixture of pure water and acetic acid to prepare solution B. In a preferred embodiment of the present invention, dextran with a molecular weight of 20w is preferred, the concentration of dextran is 3mg / ml, and the ratio of acetic acid to pure water in the solution is 100:1.

[0034] Solution B is added to solution A and stirred to dissolve, and then ultrasonically removed bubbles and refrigerated for a period of time. In a preferred embodiment of the present invention, preferably, solution A is added dropwise to solution B, the refrigeration temperature is 4°C, and the refrigeration time is 3 days.

[0035] The mixed solution was filtered and the solid product was washed with pure water. After freezing at -80°C for 12 h, the fibrous product was dried and collected using a freeze dryer.

[0036] The invention provides a novel "short fiber" carrier drug preparation method, which has the beneficial effect of having excellent encapsulation rate and release rate. It can be used as a carrier drug for treating ulcerative enteritis.

[0037] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0038] Example 1

[0039] A method for preparing a novel "short fiber" carrier drug, comprising: first dissolving the Chinese medicine monomer rutin in 10 ml of anhydrous ethanol (3 mg / ml) and dissolving it thoroughly to prepare solution A. Dissolving dextran (3 mg / ml) with a molecular weight of 20w in a mixture of pure water and acetic acid (the volume ratio of pure water to acetic acid is 100:1) to prepare solution B. Add solution A dropwise to solution B and stir to dissolve, remove bubbles by ultrasound, and refrigerate at 4°C for 3 days. Filter the above mixture, wash the solid product with pure water and collect it, freeze it at -80°C for 12 hours, and freeze-dry it to obtain a fibrous product.

[0040] Example 2

[0041] A method for preparing a novel "short fiber" carrier drug, comprising: first dissolving the Chinese medicine monomer rutin in 10 ml of anhydrous ethanol (3 mg / ml) and dissolving it thoroughly to prepare solution A. Dissolving dextran (3 mg / ml) with a molecular weight of 6w in a mixture of pure water and acetic acid (the volume ratio of pure water to acetic acid is 100:1) to prepare solution B. Add solution A dropwise to solution B and stir to dissolve, remove bubbles by ultrasound, and refrigerate at 4°C for 3 days. Filter the above mixture, wash the solid product with pure water and collect it, freeze it at -80°C for 12 hours, and freeze-dry it to obtain a fibrous product.

[0042] Example 3

[0043] A method for preparing a new "short fiber" carrier drug, comprising: first dissolving the Chinese medicine monomer rutin in 10 ml of anhydrous ethanol (3 mg / ml) and dissolving it thoroughly to prepare solution A. Dissolving dextran (3 mg / ml) with a molecular weight of 10w in a mixture of pure water and acetic acid (the volume ratio of pure water to acetic acid is 100:1) to prepare solution B. Add solution A dropwise to solution B and stir to dissolve, remove bubbles by ultrasound, and refrigerate at 4°C for 3 days. Filter the above mixture, wash the solid product with pure water and collect it, freeze it at -80°C for 12 hours, and freeze-dry it to obtain a fibrous product.

[0044] Example 4

[0045] A method for preparing a novel "short fiber" carrier drug, comprising: first dissolving the Chinese medicine monomer rutin in 10 ml of anhydrous ethanol (3 mg / ml) and dissolving it thoroughly to prepare solution A. Dissolving dextran (3 mg / ml) with a molecular weight of 15w in a mixture of pure water and acetic acid (the volume ratio of pure water to acetic acid is 100:1) to prepare solution B. Add solution A dropwise to solution B and stir to dissolve, remove bubbles by ultrasound, and refrigerate at 4°C for 3 days. Filter the above mixture, wash the solid product with pure water and collect it, freeze it at -80°C for 12 hours, and freeze-dry it to obtain a fibrous product.

[0046] Example 5

[0047] A method for preparing a novel "short fiber" carrier drug, comprising: first dissolving the Chinese medicine monomer rutin in 10 ml of anhydrous ethanol (3 mg / ml) and dissolving it thoroughly to prepare solution A. Dissolving dextran (3 mg / ml) with a molecular weight of 50w in a mixture of pure water and acetic acid (the volume ratio of pure water to acetic acid is 100:1) to prepare solution B. Add solution A dropwise to solution B and stir to dissolve, remove bubbles by ultrasound, and refrigerate at 4°C for 3 days. Filter the above mixture, wash the solid product with pure water and collect it, freeze it at -80°C for 12 hours, and freeze-dry it to obtain a fibrous product.

[0048] Example 6

[0049] A method for preparing a novel "short fiber" carrier drug, comprising: first dissolving the Chinese medicine monomer rutin in 10 ml of anhydrous ethanol (1 mg / ml) and dissolving it thoroughly to prepare solution A. Dissolving dextran (3 mg / ml) with a molecular weight of 20w in a mixture of pure water and acetic acid (the volume ratio of pure water to acetic acid is 100:1) to prepare solution B. Add solution A dropwise to solution B and stir to dissolve, remove bubbles by ultrasound, and refrigerate at 4°C for 3 days. Filter the above mixture, wash the solid product with pure water and collect it, freeze it at -80°C for 12 hours, and freeze-dry it to obtain a fibrous product.

[0050] Example 7

[0051] A method for preparing a novel "short fiber" carrier drug, comprising: first dissolving the Chinese medicine monomer rutin in 10 ml of anhydrous ethanol (2 mg / ml) and dissolving it thoroughly to prepare solution A. Dissolving dextran (3 mg / ml) with a molecular weight of 20w in a mixture of pure water and acetic acid (the volume ratio of pure water to acetic acid is 100:1) to prepare solution B. Add solution A dropwise to solution B and stir to dissolve, remove bubbles by ultrasound, and refrigerate at 4°C for 3 days. Filter the above mixture, wash the solid product with pure water and collect it, freeze it at -80°C for 12 hours, and freeze-dry it to obtain a fibrous product.

[0052] Example 8

[0053] A method for preparing a novel "short fiber" carrier drug, comprising: first dissolving the Chinese medicine monomer rutin in 10 ml of anhydrous ethanol (3 mg / ml) and dissolving it thoroughly to prepare solution A. Dissolving dextran (1 mg / ml) with a molecular weight of 20w in a mixture of pure water and acetic acid (the volume ratio of pure water to acetic acid is 100:1) to prepare solution B. Add solution A dropwise to solution B and stir to dissolve, remove bubbles by ultrasound, and refrigerate at 4°C for 3 days. Filter the above mixture, wash the solid product with pure water and collect it, freeze it at -80°C for 12 hours, and freeze-dry it to obtain a fibrous product.

[0054] Example 9

[0055] A method for preparing a novel "short fiber" carrier drug, comprising: first dissolving the Chinese medicine monomer rutin in 10 ml of anhydrous ethanol (3 mg / ml) and dissolving it thoroughly to prepare solution A. Dissolving dextran (2 mg / ml) with a molecular weight of 20w in a mixture of pure water and acetic acid (the volume ratio of pure water to acetic acid is 100:1) to prepare solution B. Add solution A dropwise to solution B and stir to dissolve, remove bubbles by ultrasound, and refrigerate at 4°C for 3 days. Filter the above mixture, wash the solid product with pure water and collect it, freeze it at -80°C for 12 hours, and freeze-dry it to obtain a fibrous product.

[0056] Example 10

[0057] A method for preparing a novel "short fiber" carrier drug, comprising: first dissolving the Chinese medicine monomer rutin in 10 ml of anhydrous ethanol (3 mg / ml) and dissolving it thoroughly to prepare solution A. Dissolving dextran (1 mg / ml) with a molecular weight of 20w in a mixture of pure water and acetic acid (the volume ratio of pure water to acetic acid is 100:1) to prepare solution B. Add solution A dropwise to solution B and stir to dissolve, remove bubbles by ultrasound, and refrigerate at 4°C for 1 day. Filter the above mixture, wash the solid product with pure water and collect it, freeze it at -80°C for 12 hours, and freeze-dry it to obtain a fibrous product.

[0058] Embodiment 11

[0059] A method for preparing a novel "short fiber" carrier drug, comprising: first dissolving the Chinese medicine monomer rutin in 10 ml of anhydrous ethanol (3 mg / ml) and dissolving it thoroughly to prepare solution A. Dissolving dextran (1 mg / ml) with a molecular weight of 20w in a mixture of pure water and acetic acid (the volume ratio of pure water to acetic acid is 100:1) to prepare solution B. Add solution A dropwise to solution B and stir to dissolve, remove bubbles by ultrasound, and refrigerate at 4°C for 2 days. Filter the above mixture, wash the solid product with pure water and collect it, freeze it at -80°C for 12 hours, and freeze-dry it to obtain a fibrous product.

[0060] Example 12

[0061] A method for preparing a novel "short fiber" carrier drug, comprising: first dissolving the Chinese medicine monomer rutin in 10 ml of anhydrous ethanol (3 mg / ml) and dissolving it thoroughly to prepare solution A. Dissolving dextran (1 mg / ml) with a molecular weight of 20w in a mixture of pure water and acetic acid (the volume ratio of pure water to acetic acid is 100:2) to prepare solution B. Add solution A dropwise to solution B and stir to dissolve, remove bubbles by ultrasound, and refrigerate at 4°C for 1 day. Filter the above mixture, wash the solid product with pure water and collect it, freeze it at -80°C for 12 hours, and freeze-dry it to obtain a fibrous product.

[0062] like Figure 1As shown, in the apparent images of the "short fiber" carrier drugs provided by Examples 1 and 10 of the present invention, the amount of carrier drug precipitation provided by Example 1 of the present invention is more obvious, indicating that the output of "short fibers" is related to time.

[0063] like Figure 2 As shown, the microscopic images of the "short fibers" of the carrier drugs provided in Examples 1, 2, 3, 4, and 5 of the present invention indicate that the carrier drugs provided by the preparation method of the present invention mainly present a "short fiber" structure.

[0064] like Figure 3 As shown, the drug loading rate statistics provided in Example 1, Example 2, Example 3, Example 4, and Example 5 of the present invention. The freeze-dried samples were immersed in PBS buffer (pH 7.4) for more than 7 days to study the in vitro drug release of RT from the co-assembled fibers. Through quantitative analysis, it was found that the drug loading of rutin was related to the molecular weight of dextran; however, excessive addition of dextran would destroy the assembly of rutin, resulting in reduced drug loading efficiency. It shows that excessive DEX will weaken the interaction between rutin and DEX, and the 20w molecular weight represented in Example 1 has the highest amount of rutin loaded.

[0065] like Figure 4 As shown, the hemolysis rate statistics provided by Example 1, Example 2, Example 3, Example 4, and Example 5 of the present invention. Equal amounts of samples (Example 1, Example 2, Example 3, Example 4, and Example 5) were placed in PBS containing red blood cells, co-cultured at 37°C for 1 hour, and then centrifuged. It was found that the carrier drug did not have any red blood cell rupture, and the OD540 was less than 1%, which indicated that all samples had excellent blood compatibility.

[0066] like Figure 5 As shown, first soak the sample in PBS and prepare it into a concentration of 10mg / ml for standby use. Taking mouse fibroblasts as an example, after the cells are spread on a 96-well plate, DMEM culture medium (containing 10% FBS and 1% double antibody) is added, and after culturing for one day to make it adhere to the wall, the sample is added and diluted with culture medium to 0.1mg / ml, and the cell activity is detected by CCK-8 kit during the gradient time (1 day and 3 days). Compared with the control group, all samples showed 100% cell viability, which shows that the embodiment of the present invention has excellent cell compatibility.

[0067] like Figure 6As shown, the weight of mice is directly related to the severity of enteritis. The mice to be modeled were given fresh 3-5% dextran sulfate sodium salt (DSS) drinking water for 7 consecutive days, and the mice in the control group drank normal water. Starting from the 3rd day, a certain dose of the drug in Example 1 and the positive drug sulfasalazine (sasp) were given every day, and the experimental mice were weighed every day. The results showed that after using the carrier drug in Example 1 of the present invention, the weight of the mice showed an upward trend, and there was no significant difference compared with the control group, which showed that the carrier drug had a significant effect on the DSS-induced UC mouse model.

[0068] like Figure 7 As shown, on the 7th day, after the UC mice were killed, their intestinal tissues were dissected and taken, and it was found that the intestinal length of the model group was significantly shortened. However, after using the carrier drug of Example 1 of the present invention, the intestinal length of the mice was significantly improved and there was no significant difference in length compared with the control group, which indicates that Example 1 has a significant therapeutic effect on mice with enteritis.

[0069] like Figure 8 As shown, on the 7th day, the UC mice were killed, and their spleen tissues were dissected and weighed. The results showed that the spleen weight ratio (ratio of spleen weight to body weight) of mice with acute enteritis was significantly increased (model group), however, the spleen ratio of mice after using the positive drug and the carrier drug was significantly reduced, indicating that the positive drug and Example 1 of the present invention can effectively treat UC, and the carrier drug has a better therapeutic effect.

[0070] like Fig. 9 As shown, the scores were scored according to the following method: 1. Mouse weight: 0 points for normal weight, 1 point for weight loss of less than 10%, 2 points for weight loss of 10-20%, 3 points for weight loss of 20-30%, and 4 points for weight loss of more than 30%. 2. Stool morphology: 0 points for normal morphology, 1 point for soft stool, 2 points for watery stool, 3 points for bloody stool, and 4 points for no stool. 3. Presence of mucus and blood: 0 points for no mucus or blood, 1 point for a small amount of mucus or blood, 2 points for mucus and blood, 3 points for a large amount of mucus and blood, and 4 points for full coverage of mucus and blood. 4. Severity of intestinal ulcers: 0 points for no ulcers, 1 point for mild ulcers, 2 points for moderate ulcers, 3 points for severe ulcers, and 4 points for complete ulcers. The results showed that the control group had the lowest score, indicating that the mice were healthy. The result of the model group was the highest, indicating that the UC mice were in the worst condition. However, the activity scores of the mice after using the positive drug and the carrier drug were significantly reduced, indicating that the positive drug and Example 1 of the present invention can effectively treat UC, and the carrier drug has a better therapeutic effect.

[0071] like Fig.10As shown, the intestinal tissue was subjected to "transcriptomics testing". Studying the types, quantities and changes of all transcription products in an organism under specific conditions, including non-coding RNAs such as mRNA and lncRNA, helps to understand the mechanism of gene expression regulation and discover key genes and pathways related to the disease. Usually, the size of the "circle" in the figure represents the number of differentially expressed genes enriched in a specific pathway. The larger the circle, the more enriched genes there are, which may indicate that the pathway has a greater degree of influence on the disease under the action of the drug. The results show that Example 1 mainly treats acute enteritis through the NOD signaling pathway.

Claims

1. A method for preparing a short fiber carrier drug, characterized in that: The following steps are involved: First, dissolve rutin in ethanol to prepare solution A; Dissolve dextran in a mixture of pure water and acetic acid to prepare solution B; Solution A is added to solution B and stirred to dissolve, and bubbles are removed by ultrasonication. The solution is refrigerated and allowed to stand for a period of time. A fibrous product is obtained through post-treatment as a short fiber carrier drug.

2. The method for preparing the short fiber carrier drug according to claim 1, characterized in that: The concentration of rutin in the solution A is 1-5 mg / ml.

3. The method for preparing the short fiber carrier drug according to claim 1, characterized in that: The molecular weight of the dextran is 6w to 50w.

4. The method for preparing the short fiber carrier drug according to claim 1, characterized in that: The pure water and acetic acid mixed solution is prepared by mixing pure water and acetic acid in a volume ratio of 50 to 110:

1.

5. The method for preparing the short fiber carrier drug according to claim 1, characterized in that: The refrigerated storage and standing conditions are: 2-6° C. refrigerated storage and standing for 2-5 days.

6. The method for preparing the short fiber carrier drug according to claim 1, characterized in that: The post-processing includes: The mixed solution was filtered after being refrigerated and the solid product was washed with pure water and collected, and freeze-dried to obtain a fibrous product.

7. The method for preparing the short fiber carrier drug according to claim 6, characterized in that: The freeze-drying conditions are: freeze-drying at -85°C to -75°C for 8 to 16 hours.

8. A short fiber carrier drug prepared according to the preparation method according to any one of claims 1 to 7.

9. Use of the short fiber carrier drug according to claim 8 in the preparation of a drug for treating ulcerative enteritis.

Images